Enhanced acyclovir delivery using w/o type microemulsion: preclinical assessment of antiviral activity using murine model of zosteriform cutaneous HSV-1 infection
Source abstract
Abstract
The present study was aimed to develop and evaluate a microemulsion-based dermal drug delivery of an antiviral agent, acyclovir. A water-in-oil microemulsion was prepared using isopropyl myristate, Tween 20, Span 20, water and dimethylsulphoxide. It was characterized for drug content, stability, globule size, pH, viscosity and ex vivo permeation through mice skin. In vivo antiviral efficacy of optimized formulation was assessed in female Balb/c mice against herpes simplex virus-I (HSV-I)-induced infection. It was observed that optimized formulation when applied 24-h post-infection could completely inhibit the development of cutaneous herpetic lesions vis-à-vis marketed cream.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Herpesvirus Infections and Treatments · Dermatology and Skin Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Pharmaceutics, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India;
Postgraduate Institute of Medical Education and Research, Chandigarh, India
References (38)
Show source-provided references
1. Ryan KJ · 2004
2. 10.1177/09563202040150030310.1177/095632020401500303 ↗
3. 10.1007/s13346-011-0036-010.1007/s13346-011-0036-0 ↗
4. 10.1016/S0166-3542(97)00024-710.1016/S0166-3542(97)00024-7 ↗
5. 10.1056/NEJM19830421308160210.1056/NEJM198304213081602 ↗
6. 10.1016/S0163-4453(83)94118-X10.1016/S0163-4453(83)94118-X ↗
7. 10.1128/AAC.29.5.73010.1128/AAC.29.5.730 ↗
8. 10.1111/1523-1747.ep1245694810.1111/1523-1747.ep12456948 ↗
9. 10.1016/S0169-409X(00)00103-410.1016/S0169-409X(00)00103-4 ↗
10. 10.1016/j.addr.2003.10.02510.1016/j.addr.2003.10.025 ↗
11. Hua N · Zhongguo Zhong Yao Za Zhi · 2008 · 33 · 2875
12. 10.1002/jps.1016010.1002/jps.10160 ↗
13. 10.1016/j.jaad.2007.04.00810.1016/j.jaad.2007.04.008 ↗
14. 10.1016/S0168-3659(01)00524-710.1016/S0168-3659(01)00524-7 ↗
15. 10.1081/DDC-10010225110.1081/DDC-100102251 ↗
16. 10.1080/1071754070160374610.1080/10717540701603746 ↗
17. 10.1080/0363904060115029410.1080/03639040601150294 ↗
18. 10.1080/0363904070183374010.1080/03639040701833740 ↗
19. 10.1016/j.jconrel.2003.11.02210.1016/j.jconrel.2003.11.022 ↗
20. 10.1016/j.addr.2007.05.00810.1016/j.addr.2007.05.008 ↗
21. 10.1208/s12249-015-0464-010.1208/s12249-015-0464-0 ↗
22. 10.1023/A:101192752162710.1023/A:1011927521627 ↗
23. 10.3109/1061186X.2015.104851810.3109/1061186X.2015.1048518 ↗
24. 10.1016/j.colsurfa.2009.03.02910.1016/j.colsurfa.2009.03.029 ↗
25. 10.3109/10717544.2014.92306710.3109/10717544.2014.923067 ↗
26. 10.1016/S0378-5173(03)00364-810.1016/S0378-5173(03)00364-8 ↗
27. 10.1016/j.ijpharm.2009.05.01910.1016/j.ijpharm.2009.05.019 ↗
28. 10.1016/j.ejpb.2007.10.01810.1016/j.ejpb.2007.10.018 ↗
29. 10.1081/DDC-12002545810.1081/DDC-120025458 ↗
30. 10.1016/j.ijpharm.2006.07.02710.1016/j.ijpharm.2006.07.027 ↗
31. 10.1128/AAC.44.1.30-38.200010.1128/AAC.44.1.30-38.2000 ↗
32. 10.1016/j.phymed.2007.09.00310.1016/j.phymed.2007.09.003 ↗
33. 10.1007/BF0131099810.1007/BF01310998 ↗
34. 10.3109/21691401.2016.116371610.3109/21691401.2016.1163716 ↗
35. 10.3109/21691401.2014.88701810.3109/21691401.2014.887018 ↗
36. 10.1111/j.2042-7158.1981.tb11756.x10.1111/j.2042-7158.1981.tb11756.x ↗
37. 10.1111/j.2042-7158.1964.tb07545.x10.1111/j.2042-7158.1964.tb07545.x ↗
38. Wang F · 1998 · 1076